Phase 2
Completed N=108
Acute Hip Fracture Study in Patients 65 Years or Greater
Source: ClinicalTrials.gov NCT02578095 ↗Enrolled (actual)
108
Serious AEs
13.0%
Results posted
Dec 2025
Primary outcomePrimary: Efficacy in Hip Fracture Patients Confirmed by DXA Scan. — 0; 4.75; 7.15; 9.08 PBO adjusted percent change — p=0.0032
Summary
This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment.
Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be eligible for participation 3-7 weeks post-injury.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Efficacy in Hip Fracture Patients Confirmed by DXA Scan. |
0; 4.75; 7.15; 9.08 | 0.0032 sig |
Eligibility Criteria
Inclusion Criteria
- Males or females ≥65 years old who are recovering from a hip fracture (occurring 3-7 weeks prior) with no residual surgical issues will be eligible for participation.
Exclusion Criteria
- Pathological fracture (e.g. fracture due to Paget's disease of bone, malignancy, etc.). Fracture due to postmenopausal osteoporosis is not considered pathological for this trial.
Data sourced from ClinicalTrials.gov (NCT02578095). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.